MAPT and Alzheimer disease: Surprisingly, LM11A‐24 and LM11A also alleviated behavioral deficits, reversed neurite dystrophy, and reduced tau misfolding and phosphorylation as well as inflammatory changes in the hAPPLond/Swe and Tg2576 mouse models of AD (Knowles et al. 2013; Simmons et al. 2014; Nguyen et al. 2014).